News & Updates

Myeloma patients may benefit from mezigdomide-dexamethasone doublet

08 Dec 2023 by

In a study evaluating heavily pretreated patients with relapsed and refractory multiple myeloma (R/R MM), the combination of mezigdomide and dexamethasone showed promising preliminary efficacy, with myelosuppression and infection as primary toxicities.

Myeloma patients may benefit from mezigdomide-dexamethasone doublet

08 Dec 2023

Concizumab holds promise for patients with haemophilia A or B with inhibitors

07 Dec 2023 by

In patients with haemophilia A (PwHA) or B (PwHB) with inhibitors, annualized bleeding rate (ABR) was lower with daily subcutaneous (SC) concizumab prophylaxis than with on-demand treatment, findings from the phase IIIa explorer7 trial have shown.

Concizumab holds promise for patients with haemophilia A or B with inhibitors

07 Dec 2023

Severe nonadherence to hydroxychloroquine for lupus may have adverse consequences

07 Dec 2023

Among patients receiving hydroxychloroquine for systemic lupus erythematosus (SLE), severe nonadherence to medication poses increased risks of SLE flare in the following year, early damage, and 5-year mortality, according to data from the SLICC* Inception Cohort.

Severe nonadherence to hydroxychloroquine for lupus may have adverse consequences

07 Dec 2023

Surgery bests oral med for boosting bone density in dialysis patients

06 Dec 2023

For patients undergoing peritoneal dialysis, parathyroidectomy yields bigger increases in the bone mineral density (BMD) of lumbar spine and femoral neck as well as decreases in osteopenia/osteoporosis, according to a study.

Surgery bests oral med for boosting bone density in dialysis patients

06 Dec 2023

Low-dose methotrexate may pose serious adverse event risk for older adults with CKD

05 Dec 2023 by

For older adults with chronic kidney disease (CKD) who are initiating a disease-modifying antirheumatic drug (DMARD), low-dose methotrexate appears to be associated with a heightened 90-day risk of serious adverse events compared with hydroxychloroquine, as shown in a study.

Low-dose methotrexate may pose serious adverse event risk for older adults with CKD

05 Dec 2023

How does combination therapy fare as second-line treatment for NSCLC with EGFR mutation?

05 Dec 2023

Combination therapy does not appear to have beneficial effects in terms of progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), and incidence of adverse events compared with monotherapy in patients with advanced nonsmall cell lung cancer (NSCLC) who failed first-line treatment with an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, a study has shown.

How does combination therapy fare as second-line treatment for NSCLC with EGFR mutation?

05 Dec 2023

NOACs help improve outcomes in AF with vascular disease

05 Dec 2023 by

A history of vascular disease appears to contribute to worse long-term outcomes in patients with atrial fibrillation (AF), but treatment with oral anticoagulation (OAC) helps, suggests a recent study.

NOACs help improve outcomes in AF with vascular disease

05 Dec 2023

Novel therapies tied to drop in colectomy rate in paediatric UC

05 Dec 2023

The risk of colectomy in paediatric onset ulcerative colitis (UC) has significantly decreased at the population level along with an increase in the use of immunosuppressants and antitumour necrosis factor (anti-TNF), reports a study.

Novel therapies tied to drop in colectomy rate in paediatric UC

05 Dec 2023

Remibrutinib improves CSU symptoms in phase III trials

05 Dec 2023 by

Treatment with the investigational, oral Bruton’s tyrosine kinase (BTK) inhibitor remibrutinib improves symptoms in patients with chronic spontaneous urticaria (CSU) inadequately controlled on antihistamines, the phase III REMIX-1 and -2 studies have shown.

Remibrutinib improves CSU symptoms in phase III trials

05 Dec 2023

Add-on recaticimab cuts bad cholesterol in non-FH, mixed hyperlipidaemia patients

05 Dec 2023 by

In the phase III REMAIN-2 trial, add-on recaticimab – a novel, long-acting anti-PCSK9 monoclonal antibody (mAb) – led to reductions in bad cholesterol and other lipids in patients with non-familial hypercholesterolaemia (non-FH) and mixed hyperlipidaemia inadequately controlled on background statin therapy.

Add-on recaticimab cuts bad cholesterol in non-FH, mixed hyperlipidaemia patients

05 Dec 2023

News & Updates

Filter by Specialty:

Specialty:

Myeloma patients may benefit from mezigdomide-dexamethasone doublet

Myeloma patients may benefit from mezigdomide-dexamethasone doublet

Concizumab holds promise for patients with haemophilia A or B with inhibitors

Concizumab holds promise for patients with haemophilia A or B with inhibitors

Severe nonadherence to hydroxychloroquine for lupus may have adverse consequences

Severe nonadherence to hydroxychloroquine for lupus may have adverse consequences

Surgery bests oral med for boosting bone density in dialysis patients

Surgery bests oral med for boosting bone density in dialysis patients

Low-dose methotrexate may pose serious adverse event risk for older adults with CKD

Low-dose methotrexate may pose serious adverse event risk for older adults with CKD

How does combination therapy fare as second-line treatment for NSCLC with EGFR mutation?

How does combination therapy fare as second-line treatment for NSCLC with EGFR mutation?

NOACs help improve outcomes in AF with vascular disease

NOACs help improve outcomes in AF with vascular disease

Novel therapies tied to drop in colectomy rate in paediatric UC

Novel therapies tied to drop in colectomy rate in paediatric UC

Remibrutinib improves CSU symptoms in phase III trials

Remibrutinib improves CSU symptoms in phase III trials

Add-on recaticimab cuts bad cholesterol in non-FH, mixed hyperlipidaemia patients

Add-on recaticimab cuts bad cholesterol in non-FH, mixed hyperlipidaemia patients